Literature DB >> 21233418

High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy.

Laura Gonzalez-Malerva1, Jaehong Park, Lihua Zou, Yanhui Hu, Zahra Moradpour, Joseph Pearlberg, Jacqueline Sawyer, Hallam Stevens, Ed Harlow, Joshua LaBaer.   

Abstract

Resistance to tamoxifen in breast cancer patients is a serious therapeutic problem and major efforts are underway to understand underlying mechanisms. Resistance can be either intrinsic or acquired. We derived a series of subcloned MCF7 cell lines that were either highly sensitive or naturally resistant to tamoxifen and studied the factors that lead to drug resistance. Gene-expression studies revealed a signature of 67 genes that differentially respond to tamoxifen in sensitive vs. resistant subclones, which also predicts disease-free survival in tamoxifen-treated patients. High-throughput cell-based screens, in which >500 human kinases were independently ectopically expressed, identified 31 kinases that conferred drug resistance on sensitive cells. One of these, HSPB8, was also in the expression signature and, by itself, predicted poor clinical outcome in one cohort of patients. Further studies revealed that HSPB8 protected MCF7 cells from tamoxifen and blocked autophagy. Moreover, silencing HSBP8 induced autophagy and caused cell death. Tamoxifen itself induced autophagy in sensitive cells but not in resistant ones, and tamoxifen-resistant cells were sensitive to the induction of autophagy by other drugs. These results may point to an important role for autophagy in the sensitivity to tamoxifen.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233418      PMCID: PMC3033257          DOI: 10.1073/pnas.1018157108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  Overview of tyrosine kinase inhibitors in clinical breast cancer.

Authors:  A Agrawal; E Gutteridge; J M W Gee; R I Nicholson; J F R Robertson
Journal:  Endocr Relat Cancer       Date:  2005-07       Impact factor: 5.678

Review 2.  Mechanisms of tamoxifen resistance.

Authors:  Alistair Ring; Mitch Dowsett
Journal:  Endocr Relat Cancer       Date:  2004-12       Impact factor: 5.678

3.  MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products.

Authors:  J V Duncia; J B Santella; C A Higley; W J Pitts; J Wityak; W E Frietze; F W Rankin; J H Sun; R A Earl; A C Tabaka; C A Teleha; K F Blom; M F Favata; E J Manos; A J Daulerio; D A Stradley; K Horiuchi; R A Copeland; P A Scherle; J M Trzaskos; R L Magolda; G L Trainor; R R Wexler; F W Hobbs; R E Olson
Journal:  Bioorg Med Chem Lett       Date:  1998-10-20       Impact factor: 2.823

4.  Subpopulations of MCF7 cells separated by Percoll gradient centrifugation: a model to analyze the heterogeneity of human breast cancer.

Authors:  M Resnicoff; E E Medrano; O L Podhajcer; A I Bravo; L Bover; J Mordoh
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

5.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

6.  The significance of autophagy in cancer.

Authors:  Grace Ng; Jingxiang Huang
Journal:  Mol Carcinog       Date:  2005-08       Impact factor: 4.784

7.  Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.

Authors:  Hayato Takeuchi; Yasuko Kondo; Keishi Fujiwara; Takao Kanzawa; Hiroshi Aoki; Gordon B Mills; Seiji Kondo
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

8.  Building a human kinase gene repository: bioinformatics, molecular cloning, and functional validation.

Authors:  Jaehong Park; Yanhui Hu; T V S Murthy; Fredrik Vannberg; Binghua Shen; Andreas Rolfs; Jessica E Hutti; Lewis C Cantley; Joshua Labaer; Ed Harlow; Leonardo Brizuela
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-31       Impact factor: 11.205

9.  Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.

Authors:  Maurice P H M Jansen; John A Foekens; Iris L van Staveren; Maaike M Dirkzwager-Kiel; Kirsten Ritstier; Maxime P Look; Marion E Meijer-van Gelder; Anieta M Sieuwerts; Henk Portengen; Lambert C J Dorssers; Jan G M Klijn; Els M J J Berns
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

10.  Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells.

Authors:  S Bardon; F Vignon; P Montcourrier; H Rochefort
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

View more
  53 in total

1.  Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.

Authors:  Rong Liu; Cheng-Xian Guo; Hong-Hao Zhou
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  Annotation and cluster analysis of long noncoding RNA linked to male sex and estrogen in cancers.

Authors:  Shouping Liu; Weiwei Lai; Ying Shi; Na Liu; Lianlian Ouyang; Ziying Zhang; Ling Chen; Xiang Wang; Banglun Qian; Desheng Xiao; Qin Yan; Ya Cao; Shuang Liu; Yongguang Tao
Journal:  NPJ Precis Oncol       Date:  2020-03-03

3.  The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer.

Authors:  V Thewes; R Simon; M Hlevnjak; M Schlotter; P Schroeter; K Schmidt; Y Wu; T Anzeneder; W Wang; P Windisch; M Kirchgäßner; N Melling; N Kneisel; R Büttner; U Deuschle; H P Sinn; A Schneeweiss; S Heck; S Kaulfuss; H Hess-Stumpp; J G Okun; G Sauter; A E Lykkesfeldt; M Zapatka; B Radlwimmer; P Lichter; M Tönjes
Journal:  Oncogene       Date:  2017-03-20       Impact factor: 9.867

4.  Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells.

Authors:  Gwen E Dressing; Todd P Knutson; Matthew J Schiewer; Andrea R Daniel; Christy R Hagan; Caroline H Diep; Karen E Knudsen; Carol A Lange
Journal:  Mol Endocrinol       Date:  2014-02-25

Review 5.  MicroRNAs involved in drug resistance of breast cancer by regulating autophagy.

Authors:  Nan Wen; Qing Lv; Zheng-Gui Du
Journal:  J Zhejiang Univ Sci B       Date:  2020 Sept.       Impact factor: 3.066

Review 6.  Autophagy as a mechanism for anti-angiogenic therapy resistance.

Authors:  Ankush Chandra; Jonathan Rick; Garima Yagnik; Manish K Aghi
Journal:  Semin Cancer Biol       Date:  2019-08-28       Impact factor: 15.707

Review 7.  Tracking progesterone receptor-mediated actions in breast cancer.

Authors:  Todd P Knutson; Carol A Lange
Journal:  Pharmacol Ther       Date:  2013-11-26       Impact factor: 12.310

Review 8.  Autophagy and cancer therapy.

Authors:  Andrew Thorburn; Douglas H Thamm; Daniel L Gustafson
Journal:  Mol Pharmacol       Date:  2014-02-26       Impact factor: 4.436

9.  Identification of microRNA-regulated autophagic pathways in plant lectin-induced cancer cell death.

Authors:  L-L Fu; X Zhao; H-L Xu; X Wen; S-Y Wang; B Liu; J-K Bao; Y-Q Wei
Journal:  Cell Prolif       Date:  2012-08-08       Impact factor: 6.831

10.  Identification of novel caspase/autophagy-related gene switch to cell fate decisions in breast cancers.

Authors:  L-L Fu; Y Yang; H-L Xu; Y Cheng; X Wen; L Ouyang; J-K Bao; Y-Q Wei; B Liu
Journal:  Cell Prolif       Date:  2013-01-04       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.